Delcath Systems, Inc. (DCTH) Deep Dive Video

Summary

Delcath is a newly profitable small-cap oncology platform—mispriced after a transient revenue wobble—where REMS-driven execution and mCRC trial optionality determine whether HEPZATO becomes a niche cash cow or a breakout franchise.

View DCTH stock page · Read the DCTH research report

Loading the video player…